Guardian Pharmacy Services, Inc. amended revolving credit with Regions Bank maturing May 21, 2030.
“extend the maturity date of the revolving loan commitments from April 23, 2027 to May 21, 2030”
Source-grounded facts extracted from Guardian Pharmacy Services, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Guardian Pharmacy Services, Inc. amended revolving credit with Regions Bank maturing May 21, 2030.
“extend the maturity date of the revolving loan commitments from April 23, 2027 to May 21, 2030”
Guardian Pharmacy Services, Inc. reported the quarter ended March 31, 2026 results: revenue $336.6 million, net income $13.5 million, EPS $0.21. Guidance raised.
“announced today its financial results for the first quarter ended March 31, 2026. The Company also updated its full-year guidance. First Quarter Financial Results • Revenue of $336.6 million, up 2% year-over-year. • Residents served ended the quarter at approximately 207,000, up 10% year-over-year. • Net Income of $13.5 million, compared to $9.3 million in the”
Guardian Pharmacy Services, Inc. entered into Stock Purchase Agreement with certain holders valued at up to an aggregate of 1,833,344 shares of Class A common stock (effective 2026-03-18).
“On March 18, 2026, Guardian Pharmacy Services, Inc. (the “Company”) entered into stock purchase agreements (each, a “Stock Purchase Agreement” and collectively, the “Stock Purchase Agreements”) with certain holders (the “Holders”) of shares of the Company’s Class A common stock that were issued upon conversion of shares of the Company’s Class B common stock originally issued in connection with the Company’s corporate reorganization in September 2024.”
Thomas Salentine, Jr. was elected as Director at Guardian Pharmacy Services, Inc..
“On September 25, 2024 and upon the effectiveness of the Restated Certificate (as defined below), the size of the Board was increased to eight members and William Bindley, John Ackerman, Steve Cosler, Randall Lewis, Mary Sue Patchett and Thomas Salentine, Jr. were elected to the Board.”
Mary Sue Patchett was elected as Director at Guardian Pharmacy Services, Inc..
“On September 25, 2024 and upon the effectiveness of the Restated Certificate (as defined below), the size of the Board was increased to eight members and William Bindley, John Ackerman, Steve Cosler, Randall Lewis, Mary Sue Patchett and Thomas Salentine, Jr. were elected to the Board.”
Randall Lewis was elected as Director at Guardian Pharmacy Services, Inc..
“On September 25, 2024 and upon the effectiveness of the Restated Certificate (as defined below), the size of the Board was increased to eight members and William Bindley, John Ackerman, Steve Cosler, Randall Lewis, Mary Sue Patchett and Thomas Salentine, Jr. were elected to the Board.”
Steve Cosler was elected as Director at Guardian Pharmacy Services, Inc..
“On September 25, 2024 and upon the effectiveness of the Restated Certificate (as defined below), the size of the Board was increased to eight members and William Bindley, John Ackerman, Steve Cosler, Randall Lewis, Mary Sue Patchett and Thomas Salentine, Jr. were elected to the Board.”
John Ackerman was elected as Director at Guardian Pharmacy Services, Inc..
“On September 25, 2024 and upon the effectiveness of the Restated Certificate (as defined below), the size of the Board was increased to eight members and William Bindley, John Ackerman, Steve Cosler, Randall Lewis, Mary Sue Patchett and Thomas Salentine, Jr. were elected to the Board.”
William Bindley was elected as Director at Guardian Pharmacy Services, Inc..
“On September 25, 2024 and upon the effectiveness of the Restated Certificate (as defined below), the size of the Board was increased to eight members and William Bindley, John Ackerman, Steve Cosler, Randall Lewis, Mary Sue Patchett and Thomas Salentine, Jr. were elected to the Board.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.